Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.

Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y.

Nephrol Dial Transplant. 2006 Sep;21(9):2507-12. Epub 2006 Jun 9.

PMID:
16766543
2.

Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.

Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R.

Am J Kidney Dis. 2008 Sep;52(3):501-6. doi: 10.1053/j.ajkd.2008.04.031. Epub 2008 Jul 24.

PMID:
18653268
3.

Candesartan reduces cardiovascular events in patients on chronic haemodialysis.

Almirall J, Valenzuela MP, Lopez T.

Nephrol Dial Transplant. 2007 Jan;22(1):281; author reply 281-2. Epub 2006 Nov 3. No abstract available.

PMID:
17085461
4.

An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.

Nakamura T, Kanno Y, Takenaka T, Suzuki H; Efficacy of Candesartan on Outcome in Saitama Trial Group.

Hypertens Res. 2005 May;28(5):415-23.

PMID:
16156505
5.

Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.

Demers C, McMurray JJ, Swedberg K, Pfeffer MA, Granger CB, Olofsson B, McKelvie RS, Ostergren J, Michelson EL, Johansson PA, Wang D, Yusuf S; CHARM Investigators.

JAMA. 2005 Oct 12;294(14):1794-8.

PMID:
16219883
6.

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE).

Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa H; HIJ-CREATE Investigators.

Eur Heart J. 2009 May;30(10):1203-12. doi: 10.1093/eurheartj/ehp101. Epub 2009 Apr 4.

PMID:
19346521
7.

Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease.

Kondo J, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Kono T, Kosaka T, Yoshida T, Numaguchi Y, Matsui H, Murohara T, Okumura K.

Am Heart J. 2003 Dec;146(6):E20.

PMID:
14661009
8.

Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).

Ogihara T, Ueshima K, Nakao K, Fukiyama K, Oba K, Yasuno S, Fujimoto A, Sato T, Matsuoka H, Saruta T; CASE-J Ex Study Group.

Hypertens Res. 2011 Dec;34(12):1295-301. doi: 10.1038/hr.2011.120. Epub 2011 Aug 11.

PMID:
21833000
9.

Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.

Shiga T, Kasanuki H, Hagiwara N, Sumiyoshi T, Honda T, Haze K, Takagi A, Kawana M, Origasa H, Ogawa H; Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (Hij-Create) Investigators.

Blood Press. 2010 Dec;19(6):359-65. doi: 10.3109/08037051003802475. Epub 2010 May 24.

PMID:
20491606
10.

Rationale, design and baseline characteristics of a study to evaluate effects of candesartan on cardiovascular events after drug-eluting stent implantation in patients with ischemic heart disease.

Sakamoto T, Ogawa H, Nakao K, Koide S, Yamamoto N, Shimomura H, Matsumura T, Oshima S, Kikuta K, Oka H, Kimura K, Matsui K; 4C (Canderstan for Prevention of Cardiovascular Events after CYPHER or TAXUS Coronary Stenting) investigators.

J Atheroscler Thromb. 2013;20(5):472-80. Epub 2013 Mar 14.

11.

Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).

Yamaguchi J, Hagiwara N, Ogawa H, Koyanagi R, Kasanuki H, Takagi A, Mori F, Nagashima M, Yagi M; HIJ-CREATE Investigators.

Am J Cardiol. 2010 Sep 15;106(6):819-24. doi: 10.1016/j.amjcard.2010.05.007. Epub 2010 Aug 2.

PMID:
20816122
12.

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.

Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group.

J Hypertens. 2003 May;21(5):875-86.

PMID:
12714861
13.

Impact of candesartan on cardiovascular events after drug-eluting stent implantation in patients with coronary artery disease: The 4C trial.

Sakamoto T, Ogawa H, Nakao K, Hokimoto S, Tsujita K, Koide S, Yamamoto N, Shimomura H, Matsumura T, Oshima S, Kikuta K, Oka H, Kimura K, Matsui K; 4C (Candesartan for Prevention of Cardiovascular Events after CYPHER™ or TAXUS™ Coronary Stenting) study investigators.

J Cardiol. 2016 Apr;67(4):371-7. doi: 10.1016/j.jjcc.2015.06.009. Epub 2015 Aug 4.

14.

Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.

Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K; CASE-J Study Group.

Hypertens Res. 2009 Jun;32(6):505-12. doi: 10.1038/hr.2009.44. Epub 2009 Apr 24. Erratum in: Hypertens Res. 2009 Dec;32(12):1157.

PMID:
19390535
15.

Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.

Iseki K, Arima H, Kohagura K, Komiya I, Ueda S, Tokuyama K, Shiohira Y, Uehara H, Toma S; Olmesartan Clinical Trial in Okinawan Patients Under OKIDS (OCTOPUS) Group.

Nephrol Dial Transplant. 2013 Jun;28(6):1579-89. doi: 10.1093/ndt/gfs590. Epub 2013 Jan 25.

PMID:
23355629
16.

Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme.

Cohen-Solal A, McMurray JJ, Swedberg K, Pfeffer MA, Puu M, Solomon SD, Michelson EL, Yusuf S, Granger CB; CHARM Investigators.

Eur Heart J. 2008 Dec;29(24):3022-8. doi: 10.1093/eurheartj/ehn476. Epub 2008 Nov 5.

PMID:
18987098
17.

ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.

Ogihara T, Fujimoto A, Nakao K, Saruta T; CASE-J Trial Group.

Expert Rev Cardiovasc Ther. 2008 Oct;6(9):1195-201. doi: 10.1586/14779072.6.9.1195.

PMID:
18939907
18.

Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).

Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato T, Fukiyama K, Azuma J, Ogihara T, Saruta T, Nakao K; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.

Contemp Clin Trials. 2009 Jan;30(1):97-101. doi: 10.1016/j.cct.2008.09.006. Epub 2008 Sep 13.

PMID:
18824134
19.

Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.

Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.

Hypertension. 2008 Feb;51(2):393-8. doi: 10.1161/HYPERTENSIONAHA.107.098475. Epub 2008 Jan 2.

20.

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.

Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S; CHARM Investigators.

Am Heart J. 2006 Jul;152(1):86-92.

PMID:
16838426

Supplemental Content

Support Center